Author: admin

“Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast – 2034”

DelveInsight’s “Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast – 2034” report delivers comprehensive insights into COPD market dynamics, disease epidemiology, and treatment advancements across the 7MM (United States, EU4, United Kingdom, and Japan). The report forecasts that the COPD market size in 7MM, valued at approximately USD 16 billion in 2023, is expected to grow considerably during the forecast period (2024-2034). This growth trajectory is primarily supported by the expanding patient pool, enhanced diagnostic capabilities, and the introduction of premium-priced targeted biologics addressing specific inflammatory pathways implicated in COPD pathogenesis.

The US dominated the COPD market in 2023, representing approximately 62% of the total market share. Following the US, the EU4 and UK collectively captured the second-largest COPD market share in 2023, with Germany covering the largest share among European countries. Japan alone accounted for approximately 17% of the total COPD market in 2023 and is projected to witness substantial growth during the study period.

Download the Chronic Obstructive Pulmonary Disease Market report to understand which factors are driving the COPD therapeutic market @ Chronic Obstructive Pulmonary Disease Market Trends.

The epidemiological data presented in the report indicate key trends in incidence, demographics, and the COPD patient pool. The data reveal that approximately 44 million prevalent cases of COPD were diagnosed in 2023 in the 7MM, with 41% of these cases found in the US alone. These numbers are projected to increase during the forecast period owing to the persistent prevalence of smoking, improved diagnostic rates, and growing awareness among the patient population.

The COPD epidemiological data is segmented by total COPD diagnosed prevalent cases, subtype-specific diagnosed prevalent cases, gender-specific diagnosed prevalent cases, age-specific COPD diagnosed prevalent cases, and diagnosed prevalent cases of COPD based on severity of airflow limitation, symptoms, and exacerbation history of the patient. COPD affects men more than women, but there is a concerning trend of increasing incidence among women, primarily due to changing lifestyle patterns and potential hormonal influences. Furthermore, an age-wise analysis revealed that the highest number of cases was observed in the 55-64 year age group, especially in the US.

According to the GOLD classification in the DelveInsight report, the diagnosed prevalence of COPD based on severity of airflow limitation in Germany had the highest patient population in the GOLD 2 category.

Discover evolving trends in the COPD patient pool forecasts @ COPD Epidemiology Analysis.

The report also explores the current and evolving chronic obstructive pulmonary disease treatment landscape. The current COPD treatment landscape is categorized into three main segments: Monotherapies (including LABA, LAMA, and others), Double Combination Therapies (such as LABA + ICS, LABA + LAMA), and Triple Combination Therapies (LABA + LAMA + ICS). Among these, Double Combination Therapies generated the highest market revenue in 2023, reaching approximately USD 9 billion. Current marketed treatments include Duaklir Pressair by AstraZeneca (LON: AZN), a fixed-dose LAMA/LABA combination of two long-acting bronchodilators; DUPIXENT by Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (EPA: SAN), a monoclonal antibody targeting the alpha chain of the IL-4 receptor, among others.

The COPD treatment landscape is poised for transformation with several promising therapies in late-stage development. Key emerging drugs include, among others, Itepekimab (Sanofi/Regeneron Pharmaceuticals), a fully human monoclonal antibody that inhibits IL-33, which received Fast Track Designation from the FDA in January 2023. Another promising candidate is FASENRA (AstraZeneca), a humanized recombinant monoclonal antibody that specifically binds to the alpha chain of the IL-5R expressed on eosinophils and basophils. Other promising agents, such as NUCALA (GSK), are being evaluated for their efficacy in specific COPD subgroups, reflecting an industry-wide emphasis on precision medicine and personalized care.

Recent developments have underscored the dynamic evolution of the COPD market. The approval of novel therapies, particularly monoclonal antibodies, and the integration of digital health solutions are at the forefront of these developments, offering improved outcomes and quality of life for millions of patients worldwide.

One of the most significant recent developments is the regulatory expansion and uptake of DUPIXENT, co-developed by Regeneron Pharmaceuticals and Sanofi. In September 2024, the FDA approved DUPIXENT as the first biological therapy for adults with inadequately controlled COPD and an eosinophilic phenotype, following robust results from two Phase III trials. This landmark approval was soon followed by Japan’s Ministry of Health, Labour and Welfare granting marketing and manufacturing authorization for DUPIXENT in March 2025, further cementing its role as a transformative therapy in COPD management.

Unlock which COPD emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the COPD Drug Insights.

Beyond pharmacological advances, the 2025 update of the GOLD report has introduced several key changes that reflect the evolving understanding of COPD. Notably, the report now includes expanded guidance on spirometry interpretation using lower-limit-of-normal (LLN) values and z-scores, new sections on cardiovascular comorbidities and pulmonary hypertension in COPD, and updated recommendations for emerging therapies like dupilumab and ensifentrine. The GOLD report also addresses the impact of climate change on respiratory health, highlighting the need for adaptive strategies in the face of environmental challenges.

The future COPD treatment market is expected to be shaped by increased emphasis on phenotype-specific therapies, combination regimens with complementary mechanisms of action, and biologics targeting inflammatory pathways. With the anticipated approvals of novel agents like Itepekimab, FASENRA, and NUCALA, the COPD market is expected to experience robust growth over the forecast period. However, challenges remain in addressing disease heterogeneity, developing biomarkers for personalized treatment approaches, and improving early diagnosis rates to maximize therapeutic interventions at earlier disease stages. These unmet needs will further propel the chronic lung disease market.

Table of Contents

Related Reports

Chronic Obstructive Pulmonary Disease Pipeline Insight

Chronic Obstructive Pulmonary Disease Pipeline Insight provides comprehensive insights about the COPD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the COPD companies, including Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, and Mereo BioPharma, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Obstructive Pulmonary Disease Market Forecast 2024–2034: Competitive Intelligence & Growth Drivers for Pharma Stakeholders | DelveInsight

“Ocular Melanoma – Market Insight, Epidemiology And Market Forecast – 2034”

DelveInsight’s latest report, “Ocular Melanoma – Market Insight, Epidemiology And Market Forecast – 2034”, combines robust epidemiological data with ocular melanoma market trends, competitive landscape analysis, and patient journey assessments in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The report predicts that the ocular melanoma market is expected to grow positively in 7MM from approximately USD 340 million in 2023 during the forecast period (2024–2034). The US leads the market among 7MM, with a 60% market share in 2023, followed by the United Kingdom. Among the EU4 countries and the UK, the UK has the largest market size for ocular melanoma, while Spain holds the smallest share.

Download the Ocular Melanoma Market report to understand which factors are driving the Ocular Melanoma therapeutic market @ Ocular Melanoma Market Trends.

The report also analyzes historical and projected ocular melanoma epidemiology, segmented by ocular melanoma diagnosed incident cases, region-specific ocular melanoma cases, type-specific ocular melanoma cases, mutation-specific ocular melanoma cases, age-specific ocular melanoma cases, stage-specific ocular melanoma cases, and total treated cases of ocular melanoma.

The ocular melanoma patient pool is significant in the 7MM, with the US accounting for the highest number of diagnosed incident cases. Ocular melanoma primarily affects individuals aged 40–70, with a higher incidence in fair-skinned individuals and those with lighter eye colors. Other risk factors include dysplastic nevus syndrome, certain cutaneous nevi, and a family history of systemic and ocular cancers.

Ocular melanoma can be divided into uveal and non-uveal melanoma. Uveal melanoma comprises the larger group of ocular melanoma, with approximately 95% of all ocular melanoma cases, and includes choroidal, ciliary body, and iris melanoma. Non-uveal melanoma consists of conjunctival melanoma and other ocular melanomas originating from different sites.

Discover evolving trends in the Ocular Melanoma patient pool forecasts @ Ocular Melanoma Epidemiology Analysis.

The ocular melanoma market report also offers insights into current ocular melanoma treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM ocular melanoma market size from 2020 to 2034. Several innovative therapies have been approved by the FDA for treating ocular melanoma. KIMMTRAK (Immunocore) is a groundbreaking immunotherapy and the first FDA-approved metastatic uveal melanoma drug. Another significant therapy is HEPZATO KIT (Delcath Systems), a targeted hepatic artery infusion chemotherapy that delivers high doses of melphalan directly to the liver, where metastatic uveal melanoma often spreads, thus minimizing systemic side effects.

Additionally, immune checkpoint inhibitors such as YERVOY (BMS), which targets CTLA-4, and OPDIVO (BMS) or KEYTRUDA (Merck), which target PD-1, have been used off-label or in clinical trials for metastatic uveal melanoma; however, their efficacy in this type of melanoma is limited compared to their effectiveness in cutaneous melanoma.

DelveInsight’s analysis indicates that the ocular melanoma clinical trials market is very active, with many investigational therapies at various development stages. Notable candidates include TBio-4101 (Turnstone Biologics), LNS8801 (Linnaeus Therapeutics), IOA-244 (iOnctura), SD-101 (TriSalus Life Sciences), and BVD-523 (Dana-Farber Cancer Institut/BioMed Valley Discoveries), among others. These emerging therapies represent significant advancements in the ocular melanoma treatment landscape, providing hope for improved survival rates and quality of life for patients with limited options.

Recently, in March 2025, IDEAYA Biosciences (NASDAQ: IDYA) received FDA Breakthrough Therapy Designation for darovasertib, a novel PKC inhibitor, as a neoadjuvant treatment for uveal melanoma. This designation was granted based on phase II trial data showing significant tumor shrinkage, eye preservation, and a manageable safety profile with low rates of severe adverse events.

In January 2025, the FDA awarded orphan drug status to an aptamer drug conjugate (ApDC) treatment developed by researchers in China. This gene-based therapy precisely delivers anti-tumor drugs to cancer cells, making it safer and more effective than traditional methods such as surgery and radiotherapy. These developments signal promising progress in the ocular melanoma clinical trials market.

Unlock which Ocular Melanoma emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Ocular Melanoma Drug Insights.

The comprehensive analysis of the ocular melanoma market indicates promising growth prospects through 2034, supported by advancements in diagnostics and therapeutics, increasing prevalence of the disease, and rising healthcare investments globally. Stakeholders across the pharmaceutical industry, healthcare providers, and investors can leverage these insights to navigate the evolving landscape effectively and contribute to improved patient outcomes in ocular melanoma management.

Table of Contents

Related Reports

Melanoma Pipeline Insight

Melanoma Pipeline Insight provides comprehensive insights about the melanoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, and Iovance Biotherapeutics, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ocular Melanoma Market Analysis: Rising Prevalence, Breakthrough Therapies & Market Trends Through 2034 | DelveInsight

“Glioma Market Insight, Epidemiology and Market Forecast report”

Key Diffuse Midline Glioma Market Highlights

• MODEYSO’s FDA approval is expected to be a key diffuse midline glioma market driver, given its first-in-class status as a targeted therapy for H3 K27M-mutant tumors.

• Diffuse midline glioma represents a subset of the broader glioma patient population, with the total glioma market comprising approximately 47,800 incident cases across the 7MM in 2023.

• Diffuse Midline Glioma Companies: Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Chimerix (NASDAQ: CMRX), BrainChild Bio (private company – no public ticker), SonALAsense (private company – no public ticker), Kintara Therapeutics (NASDAQ: KTRA), Bristol Myers Squibb (NYSE: BMY), and others.

• According to DelveInsight’s analysis, the total glioma market size was approximately USD 1 billion in 2023, with the US accounting for ~USD 650 million, and the market is projected to grow significantly in the coming decade.

Market Impact and Diffuse Midline Glioma Epidemiology

According to DelveInsight’s Glioma Market Insight, Epidemiology and Market Forecast report, there is a critical unmet medical need in pediatric brain cancers, with diffuse midline glioma representing one of the most aggressive and challenging malignancies. The condition predominantly affects children and young adults, with H3 K27M mutations found in approximately 60-80% of diffuse midline gliomas, making it a well-defined molecular target for therapeutic intervention.

Diffuse midline glioma is characterized by aggressive growth patterns, infiltrative nature, and resistance to conventional therapies including surgery, radiation, and chemotherapy. The tumors typically arise in critical brain regions, including the brainstem (particularly the pons), thalamus, and spinal cord, making complete surgical resection impossible and leading to devastating neurological consequences. Prior to MODEYSO’s approval, treatment options were limited to palliative care and experimental therapies, with median survival typically less than 12 months from diagnosis.

The H3 K27M mutation creates a distinct epigenetic landscape that drives tumor growth and resistance to standard treatments. This mutation is found predominantly in pediatric high-grade gliomas and represents a unique therapeutic target that distinguishes these tumors from adult glioblastomas and other brain cancers.

Furthermore, the report highlights that the glioma treatment market is expected to witness significant positive shifts owing to several products in development, with MODEYSO representing the first breakthrough specifically targeting the underlying molecular driver of this devastating disease.

Download the Glioma Market report to understand which other factors are driving the therapeutic market @ Glioma Market Trends.

MODEYSO Treatment Approach

MODEYSO represents a first-in-class, brain-penetrant small molecule inhibitor designed to target the epigenetic dysregulation caused by H3 K27M mutations. Unlike conventional chemotherapy that provides only temporary symptom control, MODEYSO addresses the root molecular mechanism driving diffuse midline glioma by modulating the aberrant chromatin landscape created by the H3 K27M mutation.

The therapy is administered orally, offering patients and families a convenient treatment option that can be given at home rather than requiring frequent hospital visits for intravenous chemotherapy. This represents a significant advancement in pediatric neuro-oncology, where previous treatments have been primarily palliative with limited efficacy and significant toxicity.

“The MODEYSO approval addresses one of the most devastating unmet medical needs in pediatric oncology,” said Bruce Cozadd, Chief Executive Officer of Jazz Pharmaceuticals. “This represents a paradigm shift from palliative care to targeted molecular therapy, offering families the first treatment specifically designed to combat the underlying genetic driver of their child’s tumor.”

MODEYSO Clinical Validation and Efficacy

The MODEYSO FDA accelerated approval was based on compelling clinical evidence demonstrating meaningful anti-tumor activity in heavily pretreated patients with H3 K27M-mutant diffuse midline glioma. The approval was supported by objective response rate and duration of response data from clinical trials, representing the first demonstration of meaningful clinical activity in this historically treatment-refractory tumor type.

Key clinical outcomes include radiographic tumor responses, improved neurological function, and extended progression-free survival compared to historical controls. The therapy demonstrated a manageable safety profile with adverse events primarily consisting of manageable gastrointestinal and hematologic toxicities, representing a favorable risk-benefit profile for patients facing this terminal diagnosis.

The accelerated approval pathway reflects the FDA’s recognition of the critical unmet need and the significant clinical benefit observed in early-phase studies, with confirmatory trials ongoing to further establish long-term efficacy and safety.

Diffuse Midline Glioma Competitive Landscape and Market Positioning

MODEYSO enters a treatment landscape that has historically provided no effective therapeutic options for H3 K27M-mutant diffuse midline glioma. Current standard-of-care approaches include maximal safe surgical resection followed by focal radiation therapy, with chemotherapy offering limited benefit. The glioma competitive landscape has been dominated by supportive care measures and experimental therapies with minimal efficacy.

The broader competitive ecosystem includes established glioma companies developing treatments for various glioma subtypes, including Bayer, Saivita Biopharma, Northwest Biotherapeutics, and others, focusing on different molecular targets and approaches. However, MODEYSO represents the first molecularly-targeted therapy specifically approved for H3 K27M-mutant tumors, providing unprecedented competitive differentiation in this underserved patient population.

BrainChild Bio recently received both FDA Breakthrough Therapy Designation and RMAT (Regenerative Medicine Advanced Therapy) designation for its B7-H3-targeting autologous CAR T-cell therapy in diffuse intrinsic pontine glioma (DIPG), representing emerging competition in the immunotherapy space.

Explore the Glioma Drug Battle: MODEYSO vs. other emerging therapies. Discover how these breakthrough Glioma therapies compare in efficacy, safety, cost, and market impact @ Glioma Drugs Market.

Emerging Diffuse Midline Glioma Pipeline Therapies

Several companies are actively developing next-generation therapies for diffuse midline glioma and related pediatric brain tumors. BrainChild Bio is advancing its B7-H3-targeting CAR T-cell therapy following promising survival results in the Phase 1 BrainChild-03 trial, with both Breakthrough Therapy and RMAT designations from the FDA.

Chimerix submitted an NDA in January 2025 for accelerated approval of dordaviprone (the same compound as MODEYSO) for patients with recurrent H3 K27M-mutant diffuse glioma, with priority review requested and a target action date in Q3 2025, indicating potential label expansion or competitive entry.

Furthermore, the diffuse midline glioma pipeline includes companies developing innovative approaches such as epigenetic modulators, immunotherapies, oncolytic viruses, and novel drug delivery systems. The emergence of targeted therapies like MODEYSO validates the H3 K27M mutation as a druggable target and may accelerate the development of next-generation inhibitors with improved efficacy and safety profiles.

Discover more Glioma pipeline therapies and the clinical development progress they are making @ Glioma Clinical Pipeline.

Broader MODEYSO Therapeutic Pipeline

Beyond diffuse midline glioma, Jazz Pharmaceuticals is likely investigating dordaviprone’s potential in other H3 K27M-mutant malignancies and related epigenetic targets. The company’s focus on rare diseases and specialized patient populations positions them well to expand MODEYSO’s indications to other pediatric cancers with similar molecular drivers.

The FDA’s Rare Pediatric Disease Designation for dordaviprone provides additional regulatory incentives and may accelerate development in related indications, potentially expanding the addressable patient population and market opportunity significantly.

Industry Expert Perspective

Leading pediatric neuro-oncologists emphasize the significance of molecularly targeted approaches in diffuse midline glioma. “The approval of MODEYSO represents a historic breakthrough in pediatric brain cancer treatment,” commented experts in the field. “For the first time, we have a therapy that specifically targets the molecular driver of these devastating tumors, moving beyond one-size-fits-all chemotherapy to precision medicine approaches tailored to each tumor’s genetic profile.”

Learn more about what other Industry experts are saying about MODEYSO FDA Approval and how it will impact the Glioma treatment market @ Key Opinion Leaders on Glioma Market.

Looking Forward

The MODEYSO FDA approval represents a watershed moment in pediatric neuro-oncology and demonstrates the potential for precision medicine approaches to address the most challenging pediatric malignancies. DelveInsight’s analysts emphasize that the lack of effective treatments for H3 K27M-mutant diffuse midline glioma has represented one of the most pressing unmet needs in pediatric oncology, with families facing a universally fatal diagnosis with no approved therapeutic options.

As the pharmaceutical industry continues advancing toward molecularly-targeted therapies in pediatric cancer, MODEYSO’s success validates the approach of targeting specific genetic drivers and may accelerate development of similar precision medicine approaches in other rare pediatric malignancies with well-defined molecular targets.

Table of Contents

1. Key Insights

2. Executive Summary of Glioma

3. Competitive Intelligence Analysis for Glioma

4. Glioma Market Overview at a Glance

5. Glioma: Disease Background and Overview

6. Glioma Patient Journey

7. Glioma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Glioma Unmet Needs

10. Key Endpoints of Glioma Treatment

11. Glioma Marketed Products

12. Glioma Emerging Therapies

13. Glioma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Glioma

17. KOL Views

18. Glioma Market Drivers

19. Glioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight Business Research

DelveInsight is a leading market research and consulting firm specializing in pharmaceutical and healthcare sectors. We provide comprehensive market intelligence, competitive analysis, and strategic insights to guide decision-making for life science companies globally.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Midline Glioma Treatment Landscape: FDA Approves MODEYSO, First Targeted Therapy for H3 K27M-Mutant Tumors | DelveInsight’s Perspective on Market Impact, Competitive Landscape, Pipeline

“CAR-T Cell Therapy Market Insight, Epidemiology and Market Forecast Report”

Key CAR-T Cell Therapy Market Highlights

• Kite’s acquisition of Interius strengthens its position in a CAR-T market expected to witness growth at a considerable CAGR through 2032.

• The global CAR-T cell therapy pipeline encompasses 250+ companies and 500+ drugs in development, representing unprecedented innovation in cancer immunotherapy.

• CAR-T Cell Therapy Companies: Gilead Sciences (NASDAQ: GILD), Novartis (NVS / NYSE: NVS), Bristol Myers Squibb (NYSE: BMY,), JW Therapeutics (HKEX: 2126), Autolus Therapeutics (NASDAQ: AUTL), Allogene Therapeutics (NASDAQ: ALLO), Cartesian Therapeutics (NASDAQ: RNAC), CARsgen Therapeutics (HKEX: 2171), Precision Biosciences (NASDAQ: DTIL), and others.

• According to DelveInsight’s analysis, the total CAR-T market size in the US across key indications totaled approximately $1.75 billion in 2023, with Non-Hodgkin’s lymphoma accounting for approximately $1.2 billion, Multiple Myeloma ~$400 million, and Acute Lymphoblastic Leukemia ~$150 million.

Market Impact and CAR-T Patient Population

According to DelveInsight’s CAR-T Cell Therapy Market Insight, Epidemiology and Market Forecast reports, the cell therapy landscape represents significant unmet medical needs across hematologic malignancies. In Non-Hodgkin’s lymphoma, approximately 126K total eligible cases for CAR-T therapy existed in the 7MM in 2023, with DLBCL standing out as the most prevalent subtype. The US CAR-T market for NHL reached approximately $1.2 billion in 2023 and is projected to experience substantial growth through 2034.

The Multiple Myeloma CAR-T segment shows robust expansion, with the US market estimated at $400 million in 2022 and expected to demonstrate positive growth through 2032. In Acute Lymphoblastic Leukemia, the total incident cases in the US comprised ~7K cases in 2023, with the CAR-T market size reaching approximately $200 million across the 7MM.

The acquisition addresses critical manufacturing and scalability challenges inherent in autologous CAR-T therapies. Current approved therapies require complex patient-specific manufacturing processes, creating supply chain bottlenecks and limiting patient access. Interius’s allogeneic NK cell platform offers potential “off-the-shelf” solutions that could dramatically improve treatment accessibility and reduce manufacturing timelines.

Download the CAR-T Cell Therapy Market report to understand which other factors are driving the therapeutic market @ CAR-T Cell Therapy Market Trends.

Interius BioTherapeutics’ Technology Platform

Interius BioTherapeutics brings a proprietary allogeneic natural killer (NK) cell engineering platform designed to overcome limitations of current autologous CAR-T approaches. The company’s technology focuses on developing off-the-shelf NK cell therapies that can be administered without extensive patient-specific manufacturing requirements. Unlike traditional CAR-T cells that require weeks of manufacturing from each patient’s T cells, Interius’s platform enables rapid deployment of pre-manufactured cellular therapies.

“The acquisition of Interius represents a strategic evolution in our cell therapy capabilities,” said Christi Shaw, CEO of Kite Pharma. “Their innovative NK cell platform complements our established CAR-T portfolio and positions us to deliver next-generation therapies that can reach more patients faster while potentially reducing manufacturing complexities and costs.”

Strategic Validation and Market Positioning

The $350 million acquisition validates the growing importance of allogeneic cell therapies in addressing current market limitations. Kite’s existing portfolio includes market-leading therapies YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel), which have established strong market positions across multiple hematologic indications. YESCARTA captures significant patient share in DLBCL and follicular lymphoma, while TECARTUS remains the only CD19 CAR-T approved in third-line mantle cell lymphoma.

The acquisition strengthens Kite’s competitive position against other major players including Novartis (KYMRIAH), Bristol Myers Squibb (BREYANZI, ABECMA), and emerging allogeneic developers such as Allogene Therapeutics, which is advancing cemacabtagene ansegedleucel (ALLO-501A) in Phase II trials.

CAR-T Competitive Landscape and Pipeline Innovation

The CAR-T competitive ecosystem includes 180+ companies developing 200+ pipeline candidates across various stages of development. Current approved CAR-T Cell therapies have demonstrated remarkable efficacy but face challenges including manufacturing complexity, high costs, and potential safety concerns such as cytokine release syndrome and neurotoxicity.

Key CAR-T therapies pipeline innovations include dual-targeting approaches, improved safety profiles, and expanded solid tumor applications. The CAR-T therapy companies are leveraging dual and triple targeting strategies, with players like Miltenyi Biomedicine developing CD19/20 bispecific CAR-T therapies and Novartis advancing CD79a/CD20 bispecific platforms. Approximately 90% of the current CAR-T market is dominated by aggressive B-cell NHL, with remaining segments including indolent B-cell NHL and plasma cell malignancies.

Explore more on how this deal is going to affect the CAR-T Cell Therapy competitive landscape @ CAR-T Cell Therapy Companies and Competitive Landscape.

Emerging CAR-T Pipeline Therapy Developments

The acquisition occurs amid significant pipeline activity, with notable recent developments including Autolus Therapeutics’ FDA approval of AUCATZYL (obecabtagene autoleucel) in January 2025 for relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Multiple companies are advancing next-generation approaches, including Cartesian Therapeutics’ mRNA-engineered platform (Descartes-11), CARsgen Therapeutics’ zevorcabtagene autoleucel, and various allogeneic platforms.

Furthermore, emerging CAR-T pipeline therapies are exploring novel targets beyond CD19 and BCMA, including GPRC5D, CD30, and BAFF-R signaling pathways. The pipeline demonstrates increasing focus on overcoming current limitations through improved manufacturing processes, enhanced safety profiles, and expanded target antigen coverage.

Discover more CAR-T Cell Therapy pipeline and the clinical development progress they are making @ CAR-T Cell Therapy Clinical Pipeline.

Broader Strategic Implications

Beyond immediate portfolio expansion, Kite’s acquisition of Interius positions the company for potential expansion into solid tumor applications and autoimmune diseases, where NK cell therapies may offer advantages over traditional T-cell approaches. The allogeneic platform could enable rapid clinical development across multiple indications without patient-specific manufacturing constraints.

Industry Expert Perspective

“The acquisition of Interius by Kite represents a strategic inflection point in cell therapy development,” commented leading oncology analysts. “Allogeneic NK platforms address fundamental scalability challenges in current CAR-T manufacturing while potentially expanding therapeutic applications beyond hematologic malignancies. This transaction signals increasing industry recognition that next-generation cell therapies must overcome the logistical and economic barriers limiting current treatment accessibility.”

Learn more about what other Industry experts are saying about this acquisition and how it will impact the CAR-T Cell Therapy treatment market @ Key Opinion Leaders on CAR-T Cell Therapy Market.

Looking Forward

The Interius acquisition exemplifies the CAR-T industry’s evolution toward more scalable, accessible therapeutic platforms. DelveInsight’s analysts emphasize that while autologous CAR-T therapies have demonstrated transformative clinical efficacy, manufacturing scalability and cost considerations create opportunities for innovative approaches like allogeneic NK cell platforms. As the industry continues advancing toward broader patient accessibility and expanded therapeutic applications, strategic acquisitions like Kite’s investment in Interius may define the next generation of cellular immunotherapy development.

Table of Contents

1. Key Insights

2. Executive Summary of CAR-T Cell Therapy

3. Competitive Intelligence Analysis for CAR-T Cell Therapy

4. CAR-T Cell Therapy Market Overview at a Glance

5. CAR-T Cell Therapy: Disease Background and Overview

6. CAR-T Cell Therapy Patient Journey

7. CAR-T Cell Therapy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. CAR-T Cell Therapy Unmet Needs

10. Key Endpoints of CAR-T Cell Therapy Treatment

11. CAR-T Cell Therapy Marketed Products

12. CAR-T Cell Therapy Emerging Therapies

13. CAR-T Cell Therapy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of CAR-T Cell Therapy

17. KOL Views

18. CAR-T Cell Therapy Market Drivers

19. CAR-T Cell Therapy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight Business Research

DelveInsight is a leading market research and consulting firm specializing in pharmaceutical and healthcare sectors. We provide comprehensive market intelligence, competitive analysis, and strategic insights to guide decision-making for life science companies globally.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR-T Cell Therapy Landscape: Kite Pharma Acquires Interius BioTherapeutics for $350 Million | DelveInsight’s Perspective on Market Impact, Competitive Landscape and Pipeline Innovations